Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Add To Watchlist

Recent & Breaking News (NDAQ:NKTR)

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015

PR Newswire November 5, 2015

Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets

PR Newswire October 29, 2015

Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day

PR Newswire October 8, 2015

Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies

PR Newswire October 7, 2015

Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020

PR Newswire October 6, 2015

Nektar to Host Research & Development Day for Analysts and Investors on October 8th

PR Newswire October 1, 2015

Nektar Presents Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models

PR Newswire September 21, 2015

Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market

PR Newswire September 1, 2015

R. Scott Greer Joins Inogen Board of Directors

GlobeNewswire August 6, 2015

R. Scott Greer Joins Inogen Board of Directors

GlobeNewswire August 6, 2015

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015

PR Newswire August 5, 2015

Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets

PR Newswire July 29, 2015

Columbia Pipeline to Join the S&P 500; Other Changes to S&P MidCap 400 & S&P SmallCap 600

PR Newswire June 24, 2015

Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine

PR Newswire June 2, 2015

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global Healthcare Conference in New York City

PR Newswire May 28, 2015

Nektar Therapeutics Reports Financial Results for the First Quarter of 2015

PR Newswire April 30, 2015

Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets

PR Newswire April 23, 2015

Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference

PR Newswire April 13, 2015

Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca

PR Newswire April 2, 2015

AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US

PR Newswire March 19, 2015